BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26664449)

  • 1. Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development.
    Sharma C; Sadek B; Goyal SN; Sinha S; Kamal MA; Ojha S
    Evid Based Complement Alternat Med; 2015; 2015():238482. PubMed ID: 26664449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects.
    Patil KR; Goyal SN; Sharma C; Patil CR; Ojha S
    Curr Med Chem; 2015; 22(30):3472-501. PubMed ID: 26179998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pharmacology of Phytocannabinoids.
    Turner SE; Williams CM; Iversen L; Whalley BJ
    Prog Chem Org Nat Prod; 2017; 103():61-101. PubMed ID: 28120231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.
    McCarberg BH; Barkin RL
    Am J Ther; 2007; 14(5):475-83. PubMed ID: 17890938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terpenoids, Cannabimimetic Ligands, beyond the
    Gonçalves ECD; Baldasso GM; Bicca MA; Paes RS; Capasso R; Dutra RC
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32235333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
    Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
    J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
    Gertsch J; Raduner S; Altmann KH
    J Recept Signal Transduct Res; 2006; 26(5-6):709-30. PubMed ID: 17118807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
    Di Marzo V
    Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
    Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
    J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure Δ
    Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
    Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue?
    De Luca MA; Fattore L
    Clin Ther; 2018 Sep; 40(9):1457-1466. PubMed ID: 30180974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.